Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;49(6):744-50.
doi: 10.1038/bmt.2014.55. Epub 2014 Mar 17.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

J R Passweg  1 , H Baldomero  1 , C Peters  2 , H B Gaspar  3 , S Cesaro  4 , P Dreger  5 , R F Duarte  6 , J H F Falkenburg  7 , D Farge-Bancel  8 , A Gennery  9 , J Halter  10 , N Kröger  11 , F Lanza  12 , J Marsh  13 , M Mohty  14 , A Sureda  15 , A Velardi  16 , A Madrigal  17 ; European Society for Blood and Marrow Transplantation EBMT
Collaborators, Affiliations
Free PMC article

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

J R Passweg et al. Bone Marrow Transplant. 2014 Jun.
Free PMC article

Abstract

In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT (HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants (5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Transplant rates in Europe (=total number of HSCT per 10 million inhabitants) by participating country. (a) Allogeneic transplant rates/10 million population in 2012. (b) Autologous transplant rates/10 million population in 2012.
Figure 2
Figure 2
Absolute numbers and relative proportions of indications for an HSCT in Europe in 2012. (a) Proportions of disease indications for an allogeneic HSCT in Europe in 2012. (b) Proportions of disease indications for an autologous HSCT in Europe in 2012.
Figure 3
Figure 3
Pediatric transplant rates in Europe (= total number of HSCT per 10 million inhabitants) by participating country in 2012 in both center types. (a) Allogeneic transplant rates/10 million population. (b) Autologous transplant rates/10 million population. (c) Cord blood HSCT transplant rates/10 million population.
Figure 4
Figure 4
Absolute numbers and relative proportions of indications for pediatric HSCT in the 109 dedicated centers in Europe in 2012. (a) Proportions of pediatric disease indications for an allogeneic HSCT in Europe in 2012. (b) Proportions of pediatric disease indications for an autologous HSCT in Europe in 2012.
Figure 5
Figure 5
Percentage of types of pediatric transplants performed in the 109 dedicated centers in Europe in 2012. (a) Percentage of pediatric allogeneic HSCT performed in pediatric-only centers. (b) Percentage of pediatric autologous HSCT performed in pediatric-only centers.
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826. - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–1475. - PubMed
    1. Ljungman P, Bregni M, Brune M, Cornelissen J, deWitte T, Dini G, et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219–234. - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–1624. - PMC - PubMed
    1. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant. 2011;46:174–191. - PubMed

MeSH terms